Monopar Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Stock Incentive Plan (Tables)

Note 5 - Stock Incentive Plan (Tables)

9 Months Ended

Sep. 30, 2023

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

		*Options Outstanding*
		*Number of Shares Subject to Options*				*Weighted-Average Exercise Price*
Balances at December 31, 2022			1,642,950				4.28
Granted⁽¹⁾			508,902				3.14
Forfeited⁽²⁾			(42,851	)			3.93
Balances at September 30, 2023			2,109,001				4.01
Unvested options outstanding expected to vest⁽³⁾			685,120				3.41

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Exercise Prices		*Number of Shares Subject to Options Outstanding*				*Weighted-Average Remaining Contractual Term in Years*				*Number of Shares Subject to Options Fully Vested and Exercisable*				*Weighted-Average Remaining Contractual Term in Years*
$0.001 - $5.00			1,371,895				7.21				762,978				5.79
$5.01 - $10.00			617,942				5.75				543,017				5.51
$10.01 - $15.00			113,039				6.34				111,761				6.34
$15.01 - $20.00			6,125				6.34				6,125				6.34
			*2,109,001*				*6.73*				1,423,881				5.73

Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

						*Weighted- Average*
		*Restricted*				*Grant Date*
		*Stock Units*				*Fair Value*
		*(#)*				*per Unit ($)*
Unvested balance at December 31, 2022			272,650				4.00
Granted			368,345				3.16
Vested			(169,167	)			3.84
Unvested Balance at September 30, 2023			471,828				3.83

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

		*Three Months Ended September 30,*								*Nine Months Ended September 30,*
		*2023*				*2022*				*2023*				*2022*

Stock options granted			—				4,000				508,902				582,064
Fair value of shares vested		$	226,054			$	205,397			$	754,414			$	757,976